A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and tolerability of KRN23 after a single
subcutaneous (SC) administration in subjects with X-linked hypophosphatemic
rickets/osteomalacia (XLH) in Japan or Korea.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.